Benzinga
Moderna Inc (NASDAQ: MRNA) and Generation Bio Co (NASDAQ: GBIO) have collaborated to combine the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines. "Non-viral DNA therapeutics may offer durable, redosable, titratable genetic medicines to patients suffering from rare and prevalent diseases on a global scale," said Phillip Samayoa, Chief Stra